Skip to main content

Originally published January 2, 2014 at 4:10 PM | Page modified January 3, 2014 at 9:33 AM

  • Share:
  • Comments (0)
  • Print

Cell Therapeutics gets FDA clearance to add patients to clinical trial

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >


Cell Therapeutics stock rose 8 cents or 4.2 percent, to $1.99 Thursday after the drugmaker received notice from the Food and Drug Administration that a partial clinical hold on its potential blood-related cancer treatment tosedostat has been removed and studies on the drug may continue.

The FDA in June ordered Cell Therapeutics to stop enrolling patients in its clinical trial because of the death of a 70-year-old patient from myocarditis, an inflammation of the heart muscle wall.

The FDA requested more information on patients and adverse events in the clinical trial. Cell Therapeutics couldn’t enroll new patients until the agency gave the go-ahead.

News where, when and how you want it

Email Icon

Subscribe today!

Subscribe today!

Get 8 weeks of digital access to The Seattle Times for $1



The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited content access is included with most subscriptions.

Subscriber login ►